ClinicalTrials.gg
RecruitingNCT03978039BCB-SarcomesUpdated Sep 4, 2025

National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group

An observational study in Sarcoma, sponsored by Institut Bergonié. Recruiting at 3 sites in France. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Institut Bergonié · Observational

How we know

From the registry’s dates

  • Started Jan 2010; still recruiting 16 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Sarcoma by Institut Bergonié — 6 open to participants now, 9 under way, 1 of them phase 3. Sarcoma · Institut Bergonié.

Started
2010
the only one that year
Observational
4 of 22
1 open now
Registered
12th of 22
by date

Among the 22 studies in Sarcoma by Institut Bergonié, this one is the only one that started in 2010, is one of 4 observational ones, and was the 12th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

6 of the 22 studies in Sarcoma by Institut Bergonié are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Sarcoma by Institut Bergonié, or all of them as a file.
02

Study summary

The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas [RESOS] / French expert network dedicated to the pathology of sarcomas [RREPS]), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas [NETSARC]), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples.

Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients' outcomes.

With the financial support of the French National Cancer Institute [Institut National du cancer [INCa]).

03

Conditions studied

  • Sarcoma

Browse trials for

Keywords

  • patterns of care
  • access to care
  • survival
  • experts' network
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Diagnosis of sarcoma

Eligibility criteria

Inclusion criteria :

  • Diagnosis of sarcoma
  • Diagnosis in a French Comprehensive Cancer Center
  • Any age
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Patients with sarcoma

    Patients with a sarcoma diagnosed in a French Comprehensive cancer Center

    Drug: Chemotherapy · Drug: Immunotherapeutic Agent · Drug: target treatment · Procedure: Surgery · Radiation: Radiotherapy

Interventions

  • DrugChemotherapy

    treatment as per standard of care

  • DrugImmunologic FactorsStudies of Immunologic FactorsImmunologic Factors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    treatment as per standard of care

  • Drugtarget treatment

    treatment as per standard of care

  • ProcedureSurgery

    treatment as per standard of care

  • RadiationRadiotherapy

    treatment as per standard of care

06

What researchers measure

Primary outcomes

  1. Time to next treatment (TNT)

    Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.

    Time frame: 2 years

  2. Time to next treatment (TNT)

    Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.

    Time frame: 5 years

  3. Overall survival (OS)

    Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.

    Time frame: 2 years

  4. Overall survival (OS)

    Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.

    Time frame: 5 years

07

Study locations

3 of 3 sites recruiting
  • Institut Bergonié, Comprehensive Cancer Center
    Bordeaux, France
    Recruiting
    • Maud Toulmonde, MD · Contact
    • Antoine Italiano, MD/PhD · Contact
  • Centre Léon Bérard
    Lyon, France
    Recruiting
    • Jean-Yves Blay, MD/PhD · Contact
  • Institut Gustave Roussy, Comprehensive Cancer Center
    Villejuif, France
    Recruiting
    • Axel Le Cesne, MD/PhD · Contact
08

References and documents

Publications

  • Savina M, Le Cesne A, Blay JY, Ray-Coquard I, Mir O, Toulmonde M, Cousin S, Terrier P, Ranchere-Vince D, Meeus P, Stoeckle E, Honore C, Sargos P, Sunyach MP, Le Pechoux C, Giraud A, Bellera C, Le Loarer F, Italiano A. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017 Apr 10;15(1):78. doi: 10.1186/s12916-017-0831-7. PubMed 28391775 ↗
  • Toulmonde M, Bonvalot S, Meeus P, Stoeckle E, Riou O, Isambert N, Bompas E, Jafari M, Delcambre-Lair C, Saada E, Le Cesne A, Le Pechoux C, Blay JY, Piperno-Neumann S, Chevreau C, Bay JO, Brouste V, Terrier P, Ranchere-Vince D, Neuville A, Italiano A; French Sarcoma Group. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol. 2014 Mar;25(3):735-742. doi: 10.1093/annonc/mdt577. PubMed 24567518 ↗
  • Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, Mir O, Adam J, Chevreau C, Bonvalot S, Rios M, Kerbrat P, Cupissol D, Anract P, Gouin F, Kurtz JE, Lebbe C, Isambert N, Bertucci F, Toumonde M, Thyss A, Piperno-Neumann S, Dubray-Longeras P, Meeus P, Ducimetiere F, Giraud A, Coindre JM, Ray-Coquard I, Italiano A, Le Cesne A. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017 Nov 1;28(11):2852-2859. doi: 10.1093/annonc/mdx484. PubMed 29117335 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2010 (actual). Primary completion is estimated for Dec 2030, 251 months after the start.

Of 88 non-industry observational studies under Sarcoma, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 294. This study's planned 251 months is above that.

Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 42 and three quarters within 294.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2019
First posted
Jun 6, 2019
StartActual
Jan 1, 2010
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2035
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03978039
Lead sponsor
Institut Bergonié
Collaborators
French Sarcoma Group
Responsible party
Sponsor
First posted
Jun 6, 2019
Start date
Jan 1, 2010
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Sep 4, 2025

Study contacts

Maud Toulmonde, MD
Contact
m.toulmonde@bordeaux.unicancer.fr
0556333333
Simone Mathoulin-Pélissier, MD/PhD
Contact
s.mathoulin@bordeaux.unicancer.fr
05563333
Maud Toulmonde, MD
study chair · Institut Bergonié, Bordeaux, France
Axel Le Cesne, MD/PhD
study chair · Institut Gustave Roussy, Villejuif, France
Jean-Yves Blay, MD/PhD
study chair · Centre Léon Bérard, Lyon, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion